CareDx completes validation of AlloMap Kidney clinical laboratory improvement amendments

January 12, 2022

1 min read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

CareDx Inc. announced in a press release that its AlloMap Kidney has completed validation of clinical lab improvement changes, allowing it to move forward for a commercial launch.

AlloMap Kidney is designed to be a blood-based gene expression classifier that determines immune quiescence in kidney transplant patients. Researchers tested AlloMap in a clinical trial published in Kidney360 and has shown its ability to differentiate between rejection and rejection of antibody drugs and immune quiescence.

“We are happy to have finished [Clinical Laboratory Improvement Amendments] On-schedule CLIA validation of AlloMap Kidney and one step closer to commercialization of KidneyCare, a revolutionary multimodal solution that will help clinicians more comprehensively monitor the organ health of their kidney transplant patients ”, Reg Seeto, CEO and chairman of CareDx, said in the statement.

About Terry Gongora

Check Also

Florida Consortium for Medical Marijuana Clinical Outcomes Research: A Beneficial Program

By Dr. Jeff G. Konin As Florida’s marijuana landscape changes rapidly, it’s a good time …